Stimulant boosts function
in patients recovering from depression
Send a link to a friend
[January 17, 2017]
By Kate Kelland
LONDON (Reuters) - People recovering from
depression but struggling with its effect on memory, concentration and
cognitive function may benefit from the stimulant modafinil, according
to results of a small study published on Tuesday.
|
Modafinil is a generic drug usually prescribed for sleep disorders
such as narcolepsy. But in a trial of modafinil versus placebo in
patients recovering from depression, researchers at Britain's
Cambridge University found the drug prompted significant
improvements in memory and higher scores in a test.
Describing the results as promising, Muzaffer Kaser from Cambridge's
psychiatry department explained how the effects of depression on
brain performance in everyday life are often sidelined as both
patients and doctors focus on improving mood.
"Cognitive dysfunction is an unmet need in the treatment of
depression," he said. "(Family doctors) or psychiatrists often hear
complaints of concentration or memory difficulties from patients
with depression. Our study demonstrated that modafinil may be a
feasible option."
Depression is one of the world's leading causes of disability,
affecting 350 million people globally, according to the World Health
Organization.
Almost all people with depression have problems with attention,
concentration and memory. This cognitive impairment tends to persist
even as they start to recover from depression and can make it tough
for patients to get back to work or to a fully functioning life -
also increasing the risk of relapse.
[to top of second column] |
To test whether modafinil might help, Kaser's team asked 60 people
previously diagnosed with depression to complete computerized
memory, attention and planning tasks after receiving either
modafinil or placebo.
The results showed that those on modafinil made fewer errors in two
specific types of memory, episodic memory and working memory, both
of which are important in day-to-day activities.
Barbara Sahakian, who co-led the study, said longer term studies
were now needed to see if modafinil can have a positive effect in
terms of people successfully returning to work following depression.
(Editing by Janet Lawrence)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |